A once-weekly dual GIP and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Key takeaway
Tirzepatide activates two incretin hormone receptors, GIP and GLP-1, which influence insulin secretion, appetite, and digestion.
At a glance
| FDA status | In an FDA-approved drug |
|---|---|
| 503A compounding | Eligible for 503A compounding (component of an approved drug) |
| Body areas | Metabolism & weight, Gut |
| Through ScriptMates | Prescribable by licensed providers |
| Open questions | 1 noted below |
What is tirzepatide?
Tirzepatide activates two incretin hormone receptors, GIP and GLP-1, which influence insulin secretion, appetite, and digestion.
It is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management. Partner pharmacies list compounded versions, including combinations with B12 or glycine.
Dosage forms
FDA-approved Mounjaro and Zepbound are solutions for subcutaneous injection. Compounded preparations are not FDA-approved.
Is tirzepatide FDA-approved?
Active ingredient of FDA-approved Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Compounded tirzepatide is not itself FDA-approved.
Can it be prescribed through ScriptMates?
Eligible for 503A compounding (component of an approved drug). A 503A partner pharmacy lists this peptide, and it has a lawful 503A compounding pathway.
What we could not confirm
- Approved tirzepatide is no longer in shortage, so 503A limits on compounding essentially copies apply. Whether a formulation qualifies is a prescriber and pharmacy determination.
Sources
- Drugs@FDA: Mounjaro (tirzepatide)
- Drugs@FDA: Zepbound (tirzepatide)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.